Join Growin Stock Community!

基亞3176.TW Overview

TW StockBiotech. & Medical
(No presentation for 3176)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

基亞（3176）Overall Performance

基亞（3176）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

基亞（3176） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

基亞（3176）Key Information

基亞（3176）Profile

Medigen Biotechnology Corp., a biopharmaceutical company, focuses on the development of therapies for liver diseases and cancers in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitors (ICI) for patients with esophageal cancer in Japan; and in phase II study in combination with ICI for esophageal cancer and gastric cancer patients in the United States. Medigen Biotechnology Corp. was founded in 1999 and is headquartered in Taipei, Taiwan.

基亞（3176）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
55.62%
Net Margin
-6.68%
Revenue Growth (YoY)
7.49%
Profit Growth (YoY)
10.37%
3-Year Revenue Growth
27.35%
3-Year Profit Growth
36.23%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
55.62%
Net Margin
-6.68%
Revenue Growth (YoY)
7.49%
Profit Growth (YoY)
10.37%
3-Year Revenue Growth
27.35%
3-Year Profit Growth
36.23%
default symbol

3176

基亞

30.25D

0.17%

(0.00)

  • When is 3176's latest earnings report released?

    The most recent financial report for 基亞 (3176) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 3176's short-term business performance and financial health. For the latest updates on 3176's earnings releases, visit this page regularly.

  • What is the operating profit of 3176?

    According to the latest financial report, 基亞 (3176) reported an Operating Profit of -37.83M with an Operating Margin of -9.56% this period, representing a decline of 1,278.35% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 3176's revenue growth?

    In the latest financial report, 基亞 (3176) announced revenue of 395.68M, with a Year-Over-Year growth rate of -9.38%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 3176 have?

    At the end of the period, 基亞 (3176) held Total Cash and Cash Equivalents of 891.78M, accounting for 0.14 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 3176 go with three margins increasing?

    In the latest report, 基亞 (3176) did not achieve the “three margins increasing” benchmark, with a gross margin of 41.29%%, operating margin of -9.56%%, and net margin of -15.96%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 3176's profit trajectory and future growth potential.

  • Is 3176's EPS continuing to grow?

    According to the past four quarterly reports, 基亞 (3176)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.41. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 3176?

    基亞 (3176)'s Free Cash Flow (FCF) for the period is -117.73M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 82.77% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.